Evommune
EVMN · NYSE · United States
Share price · EVMN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when EVMN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+15.0%
- 28 Oct 2026+22.3%
Nothing announced by EVMN that day or the session before.
- 16 Oct 2026-12.8%
Nothing announced by EVMN that day or the session before.
- 1 Oct 2026-12.7%
- 9 Sep 2026-17.1%
- 29 Jun 2026-40.2%
- 23 Jun 2026+7.5%
Nothing announced by EVMN that day or the session before.
- 10 Feb 2026+70.9%
- 30 Jan 2026-16.4%
Nothing announced by EVMN that day or the session before.
- 16 Jan 2026-14.3%
Nothing announced by EVMN that day or the session before.
Share of unusual movement by asset
For each asset, the share of EVMN's own-move activity since 7 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (7)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $25M | $49M+ $121M short-term inv. | $31M-$26M operating cash flow | report ↗ |
View 6 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $26M | $61M+ $141M short-term inv. | $32M-$20M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $17M | $50M+ $163M short-term inv. | $22M-$28M operating cash flow | report ↗ |
| 2025-Q3 | $10M | $20M | $28M+ $49M short-term inv. | $12M-$9.6M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $20M | $62M | $14M-$26M operating cash flow | report ↗ |
| 2025-Q1 | $3.0M | $14M | $5.9M | $15M-$24M operating cash flow | report ↗ |
| 2024-Q3 | — | $13M | $18M | $16M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $13M | $74M | $45M+ $105M short-term inv. | $17M-$76M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($164K), 9 sales ($2.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Pena Luis C. · director, President & CEO | Disposition to issuer (derivative) | 796,841 | — | — | Form 4 |
| 2026-11-13 | Bauer Eugene · director, Chief Medical Officer | Disposition to issuer (derivative) | 100,000 | — | — | Form 4 |
| 2026-11-13 | Moss Gregory S. · Chief Business & Legal Officer | Disposition to issuer (derivative) | 293,496 | — | — | Form 4 |
| 2026-11-13 | Carver Kyle · Chief Financial Officer | Disposition to issuer (derivative) | 279,408 | — | — | Form 4 |
| 2026-11-13 | Patel Jeegar Pravinkumar · Chief Scientific Officer | Disposition to issuer (derivative) | 179,619 | — | — | Form 4 |
| 2026-11-13 | Drew Janice Suzann · Chief of Dev. Operations | Disposition to issuer (derivative) | 231,274 | — | — | Form 4 |
| 2026-11-13 | MCGRAW BENJAMIN F III · director | Disposition to issuer (derivative) | 37,960 | — | — | Form 4 |
| 2026-11-13 | Cohen David E · director | Disposition to issuer (derivative) | 37,960 | — | — | Form 4 |